Genetic markers may help predict response to TNF inhibitor therapy in rheumatoid arthritis, potentially leading to more ...
TNF inhibitors offered greater protection against fractures than NSAIDs in patients with axial spondyloarthritis (axSpA).
A new tumor necrosis factor alpha (TNF-α) blocker with a unique once-monthly dosing schedule has been approved, but despite its advantages, few believe it will shake up the market. Simponi ...
ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase ...
Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce ... That ...
Opens in a new tab or window Patients with axial spondyloarthritis (axSpA) treated with tumor necrosis factor (TNF ... the impact of the timing of TNF [inhibitor] initiation and alternative ...
Study finds TNF inhibitors lower hip and spine fracture risk in axial spondyloarthritis, addressing inflammation-related ...
Background. A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform ...
A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn’s disease.A new ...